RxDoctor Payments Data

Peter Nagi

Anesthesiology · Birmingham, ALNPI 1124079058

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among anesthesiology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,639in general payments, 2019–2025

Across 59 payments — averaging $44.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$598
  • SPR Therapeutics, Inc$530
  • Abbott$405
  • Boston Scientific$289
  • Nalu Medical, Inc.$160
  • Saluda Medical Americas, Inc.$146
  • plus $512 from 12 others

What the payments were for

  • Travel & lodging$25810%
  • Food & beverage$2,38190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,639 in reported general payments places this provider in the 95th percentile of 484 anesthesiology providers in Alabama.

See all anesthesiology providers in Alabama

Medicare billing

Part B allowed, 2024
$66,053
Medicare patients
306
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl17$9,809
Buprenorphine36$6,620
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen164$3,142
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen92$2,596
Gabapentin178$2,262
Pregabalin64$864
Oxycodone Hcl25$376
Tramadol Hcl46$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$64$9,80917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 484 anesthesiology providers in Alabama.

Other anesthesiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →